PRKCA and cancer: That compound 4 shows reduced cytotoxicity, selectivity towards PKCα and also activated the downstream ERK1/2 either by the Ras →Raf →MEK1/2 →ERK1/2 or the Raf →MEK1/2 →ERK1/2 pathways, this compound can be used as a potential drug for disease states involving PKCα, such as cardiac contractility, atherogenesis, cancer and arterial thrombosis [29], [78], [79].